Indian Pharmaceutical Exports To US Exempted From President Donald Trump’s 26% Tariffs Due To Healthcare Needs

Indian Pharmaceutical Exports To US Exempted From President Donald Trump’s 26% Tariffs Due To Healthcare Needs

The US is the largest importer of pharmaceuticals from India, bringing in products in the category worth $8.73 billion during the 2024 fiscal year, according to statistics cited by the India Brand Equity Foundation (IBEF).

IANSUpdated: Thursday, April 03, 2025, 11:21 AM IST
article-image
Because of the importance of India’s pharmaceuticals to US healthcare, those exports will get a reprieve from President Donald Trump’s reciprocal tariffs, | Representational Image

New York: Because of the importance of India’s pharmaceuticals to US healthcare, those exports will get a reprieve from President Donald Trump’s reciprocal tariffs, according to the White House.

The US is the largest importer of pharmaceuticals from India, bringing in products in the category worth $8.73 billion during the 2024 fiscal year, according to statistics cited by the India Brand Equity Foundation (IBEF).

IBEF said 31.5 per cent of India’s pharmaceutical exports went to the US.

The White House factsheet issued on Wednesday after Trump’s announcement of 26 per cent reciprocal tariffs on imports from India said that pharmaceuticals were exempt.

Indian drugs, especially the generics, help hold down the costs of the US healthcare system, which is already one of the most expensive in the world.

Previewing the likely outcomes of the tariffs, ING Bank had warned that “in the absence of a deal with India, we think Trump’s tariffs will mostly drive up drug prices for US consumers” because of the wide use of generics for which India is the major supplier.

Given the importance of Indian pharmaceuticals, President Trump has exempted that category even without a deal.

IQVIA, a healthcare data and analytics company, said that four out of ten prescriptions filled in the US in 2022 were from Indian companies.

“Out of the top 10 therapy areas by prescription volume, Indian companies supplied more than half of the prescriptions for five: hypertension, mental health, lipid regulators, nervous system disorders, and antiulcerants”, it said.

IQVIA estimated that by using generics from India, rather than high-priced branded products, the US healthcare system saved $219 billion in 2022 and a total of $1.3 trillion between 2013 and 2022.

These savings dwarf the dollar values of the pharmaceutical imports from India, and 26 per cent tariffs on them would have had a domino effect across the healthcare system, especially Medicare, the government healthcare insurance system for seniors, that is already facing challengee to long-rage viability.

The White House factsheet said that copper, semiconductors, lumber, bullion, energy and certain minerals that are not available in the US are also exempt from the reciprocal tariffs.

Disclaimer: This is a syndicated feed. The article is not edited by the FPJ editorial team.

RECENT STORIES

India’s Exports To US May Fall 30% To USD 60.6 Billion This Fiscal Due To Trump Tariffs: GTRI

India’s Exports To US May Fall 30% To USD 60.6 Billion This Fiscal Due To Trump Tariffs: GTRI

Titagarh Rail Systems Bags ₹1,600-Crore Contract To Supply 108 Coaches To Mumbai Metro

Titagarh Rail Systems Bags ₹1,600-Crore Contract To Supply 108 Coaches To Mumbai Metro

DLF Q1 Profit Rises 18% To ₹763 Crore; Sales Bookings Jump 78% To Record ₹11,425 Crore

DLF Q1 Profit Rises 18% To ₹763 Crore; Sales Bookings Jump 78% To Record ₹11,425 Crore

RBI's MPC Begins Policy Deliberations Amid Growth-Tariff Concerns; Rate Decision On August 6

RBI's MPC Begins Policy Deliberations Amid Growth-Tariff Concerns; Rate Decision On August 6

CIL Targets Record 900 MT Coal Supply For FY26, Announces ₹16,000 Crore Capex For Growth And...

CIL Targets Record 900 MT Coal Supply For FY26, Announces ₹16,000 Crore Capex For Growth And...